Adoptive therapy with autologous T cells expressing chimeric T-cell receptors (chTCRs) is of potential interest for the treatment of malignancy. To limit possible T-cell-mediated damage to normal tissues that weakly express the targeted tumor antigen (Ag), we have tested a strategy for the suppression of target cell recognition by engineered T cells. Jurkat T cells were transduced with an anti-hapten chTCR under the control of a tetracycline-suppressible promoter and were shown to respond to Ag-positive (hapten-coated) but not to Ag-negative target cells. The engineered T cells were then reacted with hapten-coated target cells at different effector to target cell ratios before and after exposure to tetracycline. When the engineered T cells were treated with tetracycline, expression of the chTCR was greatly decreased and recognition of the hapten-coated target cells was completely suppressed. Tetracycline-mediated suppression of target cell recognition by engineered T cells may be a useful strategy to limit the toxicity of the approach to cancer gene therapy. Cancer Gene Therapy (2000) 7, 526 -529
R ecent studies have shown that cultured T cells can be transfected with genes encoding chimeric receptors in which ligand-binding domains, with defined tumor specificity, are linked to different signaling portions of the T-cell receptor (TCR)/CD3/ complex. [1] [2] [3] [4] [5] [6] [7] Interaction of the grafted chimeric TCR (chTCR) with its ligand on tumor cells induces cell activation, which results in secretion of cytokines, clonal proliferation, and cytolysis of tumor cells in vitro and in vivo.
However, because few tumor-associated antigens (Ags) are truly tumor-specific, 8 successful therapy with gene-modified effector cells could be associated with significant collateral damage to normal tissues. Moreover, gene modification of hematopoietic stem cells (HSC) may be preferable to modification of terminal differentiated T cells. 9 The self-renewing nature and transplantability of hematopoiesis would allow the permanent generation of a stable population of tumorspecific effector cells. However, the high affinity of binding of the single-chain antibody (scFv) moiety to its cognate Ag or the use of scFvs directed against Ags with strong cross-linking ability could result in the ligandmediated negative selection of chTCR-expressing immature lymphocytes if the targeted Ag were present in the thymic microenvironment. It would therefore be desirable to develop strategies by which engineered cells can be rendered temporarily or permanently anergic to their target Ag. This would provide the means for the suppression of T-cell-mediated damage to normal tissues after therapy with engineered cells, and it could also have implications in protocols of HSC-based immunotherapy.
We have demonstrated previously that the surface density of a chTCR molecule could be efficiently regulated using a single tetracycline-regulatable vector and that this would provide a convenient method for the pharmacologic control of Ag responsiveness to their targeted Ag. 10 However given the artificial nature of the stimulus (plastic-immobilized NIP-modified (4-hydroxy-5-iodo-3-nitrophenylacetyl) bovine serum albumin (BSA)) in this study, we have evaluated its utility in regulating T-cell responsiveness in a more physiologic setting, after stimulation with target cells expressing different Ag densities.
MATERIALS AND METHODS

Vectors, cells, and transfections
The structure of plasmid pLAV12 has been described previously; 10 it is a tetracycline-regulatable construct containing all the components of the tetracycline-regulatable system 11 and a chTCR molecule. 
Hapten modification of target cells
HeLa S3 cells were extensively washed in phosphate-buffered saline (PBS), counted, and adjusted to a concentration of 10 7 /mL. Different amounts of a fresh 50 mg/mL solution of NIP-CAP-Osu (succinimide ester of 3-nitro-4-hydroxy-5-iodophenylacetic acid spaced with caproic acid) (Genosys Biotechnologies, Cambridge, UK) in dry dimethylformamide were added to the cell suspension to give a final concentration range of 1-10 g/mL. The cells were incubated for 1 hour at 37°C and then washed three times with 15 mL of cold PBS supplemented with 10% FCS.
Flow cytometry
The expression of chTCR molecules was monitored by standard direct immunofluorescence using a fluorescein isothiocyanate-conjugated goat anti-serum to mouse -chain (Southern Biotechnology Associates, Birmingham, Ala). The relative amount of NIP bound to hapten-modified HeLa S3 cells was estimated by indirect immunofluorescence using saturating amounts of a soluble B1.8 scFv antibody fragment 13 and a fluorescein isothiocyanate-conjugated goat anti-serum to mouse -chain (Southern Biotechnology Associates). A minimum of 20,000 cells were analyzed with a FACScan (Becton Dickinson). The number of viable cells was measured cytofluorometrically, 14 and the percentage of cell loss was calculated as follows: 100 ϫ (1 Ϫ [number of viable cells receiving antigenic stimulation/number of viable cells without any treatment]).
T-cell stimulation
Jurkat 1D9 cells (5 ϫ 10 5 /mL) were preincubated for 48 hours in the absence or presence of tetracycline hydrochloride (Sigma, St. Louis, Mo), and the surface expression of chTCR was examined by FACS analysis. In each assay, 5 ϫ 10 4 effector Jurkat 1D9 cells were cocultured with target HeLa S3 cells expressing different levels of NIP-modified cell surface proteins, at various effector to target (E:T) ratios, in medium alone or in the presence of tetracycline at the same concentration as that originally used for repression. The cells were incubated in duplicate in round-bottom 96-well plates (Corn- ing, Corning, NY) at 37°C in 5% CO 2 in a final volume of 200 L. After 20 hours, cell-free supernatants were harvested and assayed for interleukin-2 (IL-2) activity using an enzymelinked immunosorbent assay kit (Genzyme Diagnostic, Cambridge, Mass).
RESULTS AND DISCUSSION
The labeling of HeLa S3 cells with different concentrations of NIP-CAP-Osu resulted in the generation of cell populations expressing different levels of hapten-modified cell surface proteins with a homogeneous pattern (Fig 1A) . No changes in cell viability were observed at concentrations of NIP that were Յ10 g/mL (data not shown). However, the labeling was not stable, and the mean fluorescence intensity after a 16-hour incubation period was only 30 -40% of that observed at 0 hours (data not shown). In an attempt to generate cell surfaces expressing NIP-modified proteins in a more stable form, cells were treated with NIP as before and then fixed with glutaraldehyde. After 16 hours of culture, the viability was not significantly affected when solutions containing Յ0.012% glutaraldehyde were used (Fig 1C) . Surface staining demonstrated that under these conditions, the amount of NIP-modified surface molecules was ϳ70% of that observed at 0 hours in each cell population (Fig 1B) .
We have demonstrated previously that the chimeric B1.8-TCR molecule is able to mediate specific recognition of its cognate Ag, either in solution or immobilized on plastic, resulting in the production of IL-2 by transfected T cells. 10, 12 In the current study, we found consistently that tetracycline-untreated chTCR-expressing Jurkat cells could be specifically triggered, after incubation with NIP-modified stimulator HeLa S3 cells, to produce IL-2 (Fig 2) . The level of IL-2 secretion was significantly higher than that observed in the same cell population in response to plastic-immobilized NIP-BSA conjugates (data not shown). This finding suggests that other adhesion molecules on HeLa S3 cells are capable of providing limited costimulation to transfected Jurkat cells. There was a clear correlation between the level of IL-2 secreted and the level of chTCR occupancy (surface density of NIP-modified proteins and E:T ratio). The level of IL-2 produced diminished when Jurkat transfectants were stimulated at E:T ratios of Ͼ1:2.5. This effect was independent of the level of hapten-modified proteins expressed on target cell surfaces and was also observed when Jurkat 1D9 cells were stimulated with plastic-immobilized NIP-BSA conjugates in the presence of unlabeled HeLa S3 cells at high E:T ratios (data not shown). This suggests an inhibitory effect due to competition for nutrients. Incubation of Jurkat 1D9 cells for 24 -48 hours in the presence of concentrations of tetracycline of Ն10 ng/mL down-regulated most surface chTCRs (Fig 1D) , 10 rendering them completely unresponsive to stimulation with cell-bound hapten even at a an E:T ratio of 1:2.5 (Fig 2) . We have shown previously that at these concentrations (Յ1 g/mL), tetracycline did not interfere with the process of T-cell activation. 10 Unlabeled HeLa S3 cells did not activate chTCR-expressing Jurkat cells (data not shown), demonstrating the specificity of the response to NIP. Nontransduced parental Jurkat cells could not be stimulated to secrete IL-2 by NIP-labeled (Fig 2) or unlabeled (data not shown) target HeLa S3 cells
In summary, we have demonstrated that engineered T cells expressing chTCRs can be rendered unresponsive to their targeted Ag even when this is expressed on a cell surface. This provides the means to render reinfused gene-modified effector cells unresponsive to their target Ag if they cause collateral damage to normal tissues. Furthermore, this finding could have implications in protocols of HSC-based immunotherapy, because it is currently believed that a major deciding factor for the fate of immature T cells is the avidity of the interaction between the TCR and the peptide-major histocompatibility complex on the interacting cells. 15 A high-avidity interaction leads to negative selection, whereas a lowavidity one leads to positive selection. 16 Although additional studies with ex vivo-modified HSCs are necessary, our results suggest that by varying the surface density of the chTCR (intermittent administration of tetracycline), it could be feasible to avoid the negative selection of genemodified HSC-derived precursor cells or even to transform a negative-selecting ligand into a positive-selecting one.
